Cardiomedex
  • home
  • About us
    • Corporate overview
    • Team
    • Ethics and Quality
    • Partners
  • CRO services
    • In vivo models
    • In vivo exploration
    • Ex vivo / in vitro assays
    • Molecular screening
  • Consulting services
  • News publications
    • Conference
    • Scientific Publications
  • Contact Us
  • Careers
Sélectionner une page
Cardiomedex to present  NASH hamster model at the AHA 2023

Cardiomedex to present NASH hamster model at the AHA 2023

par advisuel | Oct 31, 2023 | conference

Join us at the American Heart Association meeting taking place from 10th to 13th November 2023 in Philadelphia, PA, USA. Cardiomedex is very excited to be sharing the latest results confirming the clinical relevance of the diet-Induced Obese NASH Hamsterfor evaluating...
Cardiomedex to present a HFpEF hamster model at the 37thAnnual Meeting of the International Society of Heart Research (ISHR)July 10th-13th in Porto,Portugal

Cardiomedex to present a HFpEF hamster model at the 37thAnnual Meeting of the International Society of Heart Research (ISHR)July 10th-13th in Porto,Portugal

par advisuel | Juil 4, 2023 | conference

Cardiomedex will be presenting a new HFpEF hamster model at the 37th Annual Meeting of the ISHR in Porto, Portugal from 10th to 13th of July2023. This unique preclinical model will be presented during the July 10thposter session (poster #PO55) from 16:30-18:00 by...

Articles récents

  • Cardiomedex to present NASH hamster model at the AHA 2023
  • Cardiomedex to present a HFpEF hamster model at the 37thAnnual Meeting of the International Society of Heart Research (ISHR)July 10th-13th in Porto,Portugal
  • Physiogenex and Cardiomedex to present the SDT fatty rat model at ISN-World Congress of Nephrology in Bangkok, Thailand, March 30-April 2, 2023
  • Physiogenex and Cardiomedex to present a new diabetic NASH HFpEF hamster model at the Keystone conference on type 2 Diabetes therapeutics, May 1-4 in Palm Springs, CA, USA

Commentaires récents

    logo cardiomedex

    Cardiomedex is a preclinical CRO that is highly specialized in cardiovascular diseases and complications. Cardiomedex provides a wide choice of benchmarked animal models targeting heart failure with preserved or reduced ejection fraction, myocardial infarction, cardiac hypertrophy, hypertension, and anthracycline cardiotoxicity. We also offer ex vivo and in vitro models for drug development and pharmacological research. We have a decade of experience in evaluating the efficacy of our clients’ drugs using gold-standard and tailor-made experiments and our large selection of validated preclinical assays.

     

    For more information on our company and offers, please download our Corporate Presentation.

    Menu

    • CRO services
    • Consulting services
    • Scientific Publications
    • Contact Us

    Services

    • In vivo models
    • In vivo exploration
    • Ex vivo / in vitro exploration
    • Molecular screening

    Useful Menu

    • Home
    • Contact Us
    • Legal Mentions
    • Privacy Policy

    Contact

    CARDIOMEDEX

    Address: 280 rue de l’Hers, ZAC de la Masquère, 31750 Escalquens – France
    Phone: +33532097980

    For general inquiries, please contact us here.

    • Twitter
    • Linkedin
    • Viadeo
    Copyright © CARDIOMEDEX